Solesence, Inc. Common Stock (SLSN) - Total Liabilities
Based on the latest financial reports, Solesence, Inc. Common Stock (SLSN) has total liabilities worth $18.14 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Solesence, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Solesence, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Solesence, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See SLSN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Solesence, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Solesence, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Meta Biomed Co. Ltd
KQ:059210
|
Korea | ₩58.87 Billion |
|
Mastermyne Group Ltd
AU:MYE
|
Australia | AU$37.93 Million |
|
Mesa Air Group Inc
NASDAQ:MESA
|
USA | $211.57 Million |
|
Pancontinental Energy NL
AU:PCL
|
Australia | AU$580.18K |
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
Indonesia | Rp149.81 Billion |
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
Malaysia | RM810.52 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$324.52 Million |
|
Labiana Health S.A.
MC:LAB
|
Spain | €50.77 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Solesence, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Solesence, Inc. Common Stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solesence, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solesence, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Solesence, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.42 Million | -7.52% |
| 2024-12-31 | $35.06 Million | +13.16% |
| 2023-12-31 | $30.98 Million | +11.00% |
| 2022-12-31 | $27.91 Million | +33.35% |
| 2021-12-31 | $20.93 Million | -- |
About Solesence, Inc. Common Stock
Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingre… Read more